SKYE · Skye Bioscience, Inc.
$0.42
-0.08 (-16.03%)
At close · Aug 17
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“If adequate funds are not available to the Company when needed it will be required to curtail or perhaps cease operations which would, in turn, further raise substantial doubt about its ability to continue as a going concern. These conditions give rise to substantial doubt as to the Company's ability to continue as a going concern within one year after the date that these financial statements are issued.”View the 10-Q filed Aug 14, 2026
Market Cap
$17.76M
Shares
35.42M
Skye Bioscience, Inc. Earnings Call Transcripts
Every quarterly earnings call for Skye Bioscience, Inc. (SKYE) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Earnings call
FY25 · Q4
2026-03-10
Skye Bioscience, Inc. Q4 FY2025 Earnings Call
Positive tone
CBEYOND clinical data and combination results
Exposure/PK and biodistribution rationale
Namasimab CB1 mechanism and differentiation
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Skye Bioscience, Inc. Q3 FY2025 Earnings Call
Confident tone
CBEYOND Phase 2a top-line results
Discovery R&D and CB1 mechanism
Dose-ranging strategy and higher doses
Diluted EPS
$-0.32
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Skye Bioscience, Inc. Q2 FY2025 Earnings Call
Confident tone
Combination efficacy with tirzepatide
Phase IIa clinical progress and timeline
Market access and KOL feedback
Diluted EPS
$-0.44
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Skye Bioscience, Inc. Q1 FY2025 Earnings Call
Positive tone
Nimacimab Preclinical Data and Differentiation
Combination Strategy with GLP-1
Phase 2b Trial Design
Diluted EPS
$-0.28
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-20
Skye Bioscience, Inc. Q4 FY2024 Earnings Call
Confident tone
nimacimab CBeyond clinical trial
Safety profile and DSMB reviews
Accelerated topline data timeline
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Skye Bioscience, Inc. Q3 FY2024 Earnings Call
Confident tone
Preclinical data and ObesityWeek disclosure
GLP-1 / incretin landscape and combination potential
Phase 2 CBeyond obesity clinical trial execution
Diluted EPS
$-0.10
Audio
Transcript
Slides
8-K10-Q
Showing 1–6 of 6 earnings calls
Key facts
CIK
1516551
CUSIP
83086J200
13F (30d)
43 filings
43 filers
Visit website
Investor relations